Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Vascular Disorders Clear all

Conditions: Central Retinal Vein Occlusion
Interventions: Tissue Plasminogen Activator; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Retinopathy
Interventions: Blood draw; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Diabetic Macular Edema (DME)
Interventions: Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF, Sham; Drug · Other
Lead sponsor: BioAge Labs, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 16
States / cities: Bakersfield, California • Glendale, California • Mountain View, California + 13 more

Conditions: Cognitive Impairment, Progressive, Cerebral Small Vessel Diseases
Interventions: High-Speed Circuit Resistance Training, Lecture on Diet, Exercise and Cognition; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 65 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Coral Gables, Florida

Conditions: Moderate Non-proliferative Diabetic Retinopathy
Interventions: Alpha Lipoic Acid; Dietary Supplement
Lead sponsor: Ferris State University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Big Rapids, Michigan • Grand Rapids, Michigan

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions: Faricimab, Port Delivery System with Ranibizumab; Drug · Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 18
States / cities: Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more

Conditions: Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Interventions: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept; Genetic · Drug · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 25 Years to 89 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 25
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more

Conditions: Central Retinal Vein Occlusion, Choroidal Neovascularization, Age-related Macular Degeneration, Branch Retinal Vein Occlusion
Interventions: Conj flora Antibiotic resistance; Procedure
Lead sponsor: Mid Atlantic Retina; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes, Diabetic Retinopathy
Interventions: DVS supplementation; Dietary Supplement
Lead sponsor: ZeaVision, LLC; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Pomona, California • Tahlequah, Oklahoma

Conditions: Macular Edema
Interventions: Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone; Device · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Point of Care Autonomous AI diabetic retinopathy exam; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 21 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Retinopathy
Interventions: phone call contact; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Macular Edema, Cystoid, Uveitis
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy
Interventions: Squalamine Lactate Ophthalmic Solution 0.2%; Drug
Lead sponsor: Starr Muscle; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: 4 mg CLS-TA, Sham, IVT aflibercept; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more

Conditions: Exudative Age Related Macular Degeneration
Interventions: Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin; Drug · Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
Interventions: Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system; Combination Product
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: Not listed
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
Interventions: multi-component nutritional supplement capsules, multi-component dietary supplement; Dietary Supplement
Lead sponsor: ZeaVision, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Home vision monitoring using myVisionTrack®; Device
Lead sponsor: Vital Art and Science Incorporated; Industry
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Ranibizumab (Lucentis), Argon Laser; Drug · Procedure
Lead sponsor: Rocky Mountain Retina Consultants; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetic Retinopathy, Macular Edema
Interventions: aflibercept; Drug
Lead sponsor: Rishi Singh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Retinal Detachment, Diabetic Retinopathy
Interventions: Avastin (bevacizumab), Sham injection; Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Central Retinal Vein Occlusion
Interventions: Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 30
States / cities: Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more

Search by objective public record fields.

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

Biomarker of Diabetic Retinopathy

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

Circuit Training and Retina

The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye

Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

ACCESS: AI for pediatriC diabetiC Eye examS Study

Diabetic Retina Exam Rate Does Not Increase With Phone Reminders in Non-HMO Population

Vascular Endothelial Growth Factor (VEGF) in Uveitis

Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201

Diabetes Visual Function Supplement Study

Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema

Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab

Avastin for PDR (Proliferative Diabetic Retinopathy)

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion